This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Schaumberg and colleagues¹ concluded that women who receive hormone replacement therapy (HRT), especially with unopposed estrogen therapy, have an increased risk of dry eye syndrome. Although they found no medical conditions to have a confounding impact, they did not consider rosacea in the list of confounding conditions.

Clinically significant rosacea occurs in approximately 30% of menopausal women.² The diagnosis of rosacea is based on the finding of persistent erythema, prominent telangiectases, and papulopustules of the cheeks, chin, and forehead. Easy flushing or blushing due to physical exertion or consumption of hot beverages is also characteristic. Noticeably lacking are the comedones that characterize acne vulgaris. The authors' failure to include rosacea as a confounding condition is significant because of the coexistence of this cutaneous condition with ocular rosacea. Ocular rosacea is a common cause of dry eye or keratoconjunctivitis sicca.³ While the incidence of ocular rosacea is . . . [Full Text of this Article]

RELATED ARTICLE

Hormone Replacement Therapy and Dry Eye Syndrome
Debra A. Schaumberg, Julie E. Buring, David A. Sullivan, and M. Reza Dana
JAMA. 2001;286(17):2114-2119.
ABSTRACT | FULL TEXT